TY - JOUR
T1 - Favorable impact of growth hormone treatment on cholesterol levels in turner syndrome
AU - Kohno Dr., Hitoshi
AU - Igarashi, Yutaka
AU - Ozono, Keiichi
AU - Ohyama, Kenji
AU - Ogawa, Masamichi
AU - Osada, Hisao
AU - Onigata, Kazumichi
AU - Kanzaki, Susumu
AU - Seino, Yoshiki
AU - Takahashi, Hiroaki
AU - Tajima, Toshihiro
AU - Tachibana, Katsuhiko
AU - Tanaka, Hiroyuki
AU - Nishi, Yoshikazu
AU - Hasegawa, Tomonobu
AU - Fujieda, Kenji
AU - Fujita, Keinosuke
AU - Horikawa, Reiko
AU - Yokoya, Susumu
AU - Yorifuji, Toru
AU - Tanaka, Toshiaki
PY - 2012
Y1 - 2012
N2 - Background: Patients with Turner syndrome (TS) are prone to having metabolic abnormalities, such as obesity, dyslipidemia, hypertension, hyperinsulinemia and type 2 diabetes mellitus, resulting in increased risks of developing atherosclerotic diseases. Objective: To determine the effect of growth hormone (GH) therapy on serum cholesterol levels in prepubertal girls with TS enrolled in the Turner syndrome Research Collaboration (TRC) in Japan. Patients and methods: Eighty-one girls with TS were enrolled in the TRC, and their total cholesterol (TC) levels before GH therapy were compared with reported levels of healthy school-aged Japanese girls. TC levels after 1, 2 and 3 yr of GH treatment were available for 28 of the 81 patients with TS. GH was administered by daily subcutaneous injections, 6 or 7 times/wk, with a weekly dose of 0.35 mg/kg body weight. Results: Baseline TC levels revealed an age-related increase in TS that was in contrast to healthy girls showing unchanged levels. During GH therapy, TC decreased significantly after 1 yr of GH treatment and remained low thereafter. Conclusions: Girls with untreated TS showed an age-related increase in TC that was a striking contrast to healthy girls, who showed unchanged levels. GH therapy in girls with TS brought about a favorable change in TC that indicates the beneficial impact of GH on atherogenic risk.
AB - Background: Patients with Turner syndrome (TS) are prone to having metabolic abnormalities, such as obesity, dyslipidemia, hypertension, hyperinsulinemia and type 2 diabetes mellitus, resulting in increased risks of developing atherosclerotic diseases. Objective: To determine the effect of growth hormone (GH) therapy on serum cholesterol levels in prepubertal girls with TS enrolled in the Turner syndrome Research Collaboration (TRC) in Japan. Patients and methods: Eighty-one girls with TS were enrolled in the TRC, and their total cholesterol (TC) levels before GH therapy were compared with reported levels of healthy school-aged Japanese girls. TC levels after 1, 2 and 3 yr of GH treatment were available for 28 of the 81 patients with TS. GH was administered by daily subcutaneous injections, 6 or 7 times/wk, with a weekly dose of 0.35 mg/kg body weight. Results: Baseline TC levels revealed an age-related increase in TS that was in contrast to healthy girls showing unchanged levels. During GH therapy, TC decreased significantly after 1 yr of GH treatment and remained low thereafter. Conclusions: Girls with untreated TS showed an age-related increase in TC that was a striking contrast to healthy girls, who showed unchanged levels. GH therapy in girls with TS brought about a favorable change in TC that indicates the beneficial impact of GH on atherogenic risk.
KW - Growth hormone therapy
KW - Serum cholesterol
KW - Turner syndrome
UR - http://www.scopus.com/inward/record.url?scp=84862333660&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84862333660&partnerID=8YFLogxK
U2 - 10.1297/cpe.21.29
DO - 10.1297/cpe.21.29
M3 - Article
C2 - 23926408
AN - SCOPUS:84862333660
SN - 0918-5739
VL - 21
SP - 29
EP - 34
JO - Clinical Pediatric Endocrinology
JF - Clinical Pediatric Endocrinology
IS - 2
ER -
